Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

edatrexate

A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Abbreviation:	10-EdAM EDAM
Code name:	CGP-30694
Chemical structure:	10-ethyl-10-deaza-aminopterin N-[4-[1-[(2,4-diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic acid
IND number:	33873
NSC code:	626715

edatrexate

Search NCI's Drug Dictionary